Document is current
Any future updates will be listed below
-
Authors
Tuo, Qing-zhang
Liu, Yu
Xiang, Zheng
Yan, Hong-Fa
Zou, Ting
Shu, Yang
Ding, Xu-long
Zou, Jin-jun
Xu, Shuo
Tang, Fei
Gong, Yan-qiu
Li, Xiao-lan
Guo, Yu-jie https://orcid.org/0000-0002-4794-9921
Zheng, Zhao-yue
Deng, Ai-ping
Yang, Zhang-zhong
Li, Wen-jing
Zhang, Shu-ting
Ayton, Scott
Bush, Ashley I. https://orcid.org/0000-0001-8259-9069
Xu, Heng https://orcid.org/0000-0002-7748-2621
Dai, Lunzhi https://orcid.org/0000-0002-3003-8910
Dong, Biao
Lei, Peng https://orcid.org/0000-0001-5652-1962
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81722016, 82071191, 81801182)
- License Information
-
More Information
Article History
Received: 1 September 2021
Revised: 14 November 2021
Accepted: 31 January 2022
First Online: 23 February 2022
Competing interests
: A.I.B. is a shareholder in Alterity Ltd, Cogstate Ltd, Eucalyptus Pty Ltd, and Mesoblast Ltd. He is a paid consultant for and has a profit share interest in Collaborative Medicinal Development Pty Ltd. All other authors declare no competing interests.
